Auditing Clinical Outcomes after Introducing Off-Licence Prescribing of Atypical Antipsychotic Melperone for Patients with Treatment Refractory Schizophrenia

Table 2

Those 7 patients who are currently continuing with Melperone.

Age	Sex	Ethnicity	Duration illness (years)/prev. hosp.	current dose	Baseline BPRS	Followup BPRS-1 (3–6 months since baseline test)	Followup BPRS-2 (12–24 months since baseline test)	% change between baseline and BPRS-2
54	M	White Cauc.	22/2	450 mg	46	39	35	23.9%
35	F	Asian	18/3	600 mg	58	59	35	32.8%
31	M	Asian	8/4	300 mg	92	63	44	52.2%
32	M	Afro-Carib.	14/4	600 mg	66	72	72	−9.1%
34	M	Black African	5/10	500 mg	67	26	26	61.1%
24	M	Asian	10/5	500 mg	98	45	45	54.1%
36	F	Afro-Carib.	7/2	450 mg	54	28	28	48.2%